4701-96-6

Basic information

• Product Name: N-hydroxy-4,4-dimethylcyclohexanimine
• CAS NO: 4701-96-6
• Molecular Formula: C₈H₁₅NO
• Molecular Weight: 141.2108
• Mol File: 4701-96-6.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 220.7°C at 760 mmHg
• Flash Point: 119.5°C
• Density: 1.02g/cm³
• Vapor Pressure: 0.0417mmHg at 25°C
• Refractive Index: 1.503
• CAS DataBase Reference: N-hydroxy-4,4-dimethylcyclohexanimine(CAS DataBase Reference)
• NIST Chemistry Reference: N-hydroxy-4,4-dimethylcyclohexanimine(4701-96-6)
• EPA Substance Registry System: N-hydroxy-4,4-dimethylcyclohexanimine(4701-96-6)

Safety Data

• Hazardous Substances Data: 4701-96-6(Hazardous Substances Data)

Upstream product

• 1073-13-8 4,4-dimethylcyclohexenone 
• 4255-62-3 4,4-dimethylcyclohexane-1-one 

Downstream Products

• 62596-04-7 5.5-dimethylhexahydroazepin-2-one 
• 1007573-20-7 3′-({2-[(4,4-dimethylcyclohexyl)amino]ethyl}oxy)-4-biphenylcarboxamide hydrochloride 
• 1473450-60-0 NITD-304 
• 25834-99-5 CR 2863 hydrochloride 
• 33024-39-4 N'-(4,4-Dimethyl-cyclohexyl)-N-(2-fluor-aethyl)-N-nitroso-harnstoff 
• 33021-79-3 N-<2-Fluor-aethyl>-N'-<4,4-dimethyl-cyclohexyl>-harnstoff 
• 20615-18-3 4,4-dimethyl-1-cyclohexylamine 

Relevant articles and documents

Enantioselective Iridium-Catalyzed Allylation of Nitroalkanes: Entry to β-Stereogenic α-Quaternary Primary Amines

The first systematic study of simple nitronate nucleophiles in iridium-catalyzed allylic alkylation is described. Using a tol-BINAP-modified π-allyliridiumC,O-benzoate catalyst, α,α-disubstituted nitronates substitute racemic branched alkyl-substituted al

As opioid receptor antagonists or inverse agonists of the novel compounds

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

TUBULYSIN DERIVATIVES

Novel tubulysin derivatives which may be useful as cytotoxic agents to provide therapeutic benefits in the treatment of various types of cancers, alone or as drug conjugates with antibodies are provided. The tubulysin derivatives consist of a tetrapeptide scaffold comprising methyl and ethyl substituted piperidines. The tubulysin conjugates further comprise monoclonal antibody via succinimide linkers.